Abstract:Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure. Given the expansion of noninvasive diagnosis with 99mTc-pyrophosphate (99mTc-PYP) scanning, and clinical use of the transthyretin stabilizer, tafamidis, we sought to examine the interplay of planar imaging heart-to-contralateral lung (H/CL) ratio, cardiac biomarkers, and survival probability in a contemporary cohort of patients referred for noninvasive evaluation of ATTR-CM. Methods: This single-center retrospective cohort study included 351 consecutive patients who underwent a standardized imaging protocol with 99mTc-PYP scanning for the evaluation of ATTR-CM from January 1, 2018, to January 1, 2020. After the exclusion of light chain amyloidosis, patients were characterized as scan consistent with ATTR (+ATTR-CM) or scan not consistent with ATTR (-ATTR-CM) using current guidelines. Linear regression was used to examine the relationship between biomarkers and H/CL and univariate Cox proportional hazards models were used to assess the probability of transplant-free survival. Results: We included 318 patients in the analysis (n = 86 patients +ATTR-CM; n = 232 patients -ATTR-CM). The median follow-up time was 20.1 months. During the study period, 67% of +ATTR-CM patients received tafamidis (median treatment duration, 17 months). The median H/CL ratio was 1.58 (interquartile range, 1.40-1.75). An H/CL ratio of more than 1.6 or less than 1.6 did not seem to have an impact on survival probability in +ATTR-CM patients (P = .30; hazard ratio, 0.65; 95% confidence interval, 0.31-1.41). Cardiac biomarkers were poorly correlated with H/CL (troponin T, R2 = 0.024; N-terminal pro-B-type natriuretic peptide, R2 =0.023). The Gillmore staging system predicted survival probability in +ATTR-CM as well as in the entire cohort referred for scanning. There was a trend toward longer survival among those who were -ATTR-CM compared with +ATTR-CM (P = .051; hazard ratio, 0.64; 95% confidence interval, 0.40-1.00). Conclusions: At a large referral center, the intensity of 99mTc-PYP uptake (H/CL ratio) has neither correlation with cardiac biomarker concentrations nor prognostic usefulness in an analysis of intermediate term outcomes in the early therapeutics era. The H/CL ratio has diagnostic value, but offers little prognostic value in patients with ATTR-CM. Established staging schema were predictive of survival in this contemporary cohort, re-emphasizing the importance of cardiac biomarkers and renal function in assessing disease severity and prognosis.

Novel Echocardiographic Parameters For Predicting Clinical Outcomes In Transthyretin Amyloid Cardiomyopathy

Assessment of Right Atrial Function Measured with Cardiac MRI Feature Tracking for Predicting Outcomes in Patients with Dilated Cardiomyopathy.

Left Ventricular Myocardial Work Index and Short-Term Prognosis in Patients with Light-Chain Cardiac Amyloidosis: a Retrospective Cohort Study

Left atrial volume assessed by echocardiography identifies patients with high risk of adverse outcome after acute myocardial infarction

Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis

Changes in Left Ventricular Ejection Fraction and Clinical Trajectories of Transthyretin Cardiac Amyloidosis with Systolic Dysfunction

Prognostic value of left atrial volume in patients with dilated cardiomyopathy

Race, Sex, and Ejection Fraction-Based Differences in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Risk Prediction

Left Atrial Dyssynchrony During Sinus Rhythm: A Predictor For Incident Atrial Fibrillation/Flutter In Transthyretin Cardiac Amyloidosis

Implications of left atrial volume index in patients with three-vessel coronary disease: A 6.6-year follow-up cohort study

Right Ventricular Free Wall Strain Predicts ATTR Prognosis as Well as Biomarker- Based Staging Systems

Diagnostic and prognostic value of the left atrial myopathy evaluation in cardiac amyloidosis using echocardiography

The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era

Defining echocardiographic predictors of outcome in cardiac amyloidosis by subtype

Comparing left atrial indices by CMR in association with left ventricular diastolic dysfunction and adverse clinical outcomes

Association of left atrial volume with mortality among ESRD patients with left ventricular hypertrophy referred for kidney transplantation

Global Longitudinal Strain and Left Atrial Volume Index Provide Incremental Prognostic Value in Patients With Hypertrophic Cardiomyopathy

Right Ventricular Strain Improves the Echocardiographic Diagnosis and Risk Stratification of Transthyretin Cardiac Amyloidosis Among Other Phenotypes of Left Ventricular Hypertrophy

Identifying left ventricular dysfunction using prospective electrocardiogram-triggered coronary computed tomography angiography

Comparative prognostic importance of measures of left atrial structure and function in non-ischaemic dilated cardiomyopathy

Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction